Clinical Trial of Excel Rapamycin Biodegradable polymer Drug-Eluting Stent

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-06000001

Enrollment

Unknown

Registered

2006-05-02

Start date

2006-08-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Intervention:Excel Rapamycin Biodegradable polymer Drug-Eluting Stent

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patient who should be full fill the criteria of using Excel stent; 2. Each included patient should allowed to use Excel stent; 3. Complete revascularization can be achieved through one invasive operation.

Exclusion criteria

Exclusion criteria: 1. Patient do not suitable to use Excel stent, for example, not tolerant to anti-platelet drug or undergo cardiac/non-cardiac surgery recently; 2. Patient with multiple branch lesions, thus the single Excel stent cannot resolve the condition; 3. NYH Cardiac functional grading>3 or Echocardiography LVEF<0.3; 4. Patient with complete revascularization cannot be resolved by one operation.

Design outcomes

Primary

Measure	Time frame
Cardiovascular event;	—

Secondary

Measure	Time frame
Binary restenosis;Blood circulation reconstruction at the target pathological change location (TLR);2. The rate of target lesion revascularization (TLR);1. Sever acute cardiovascular events (MACE);	—

Countries

China

Contacts

Public ContactHan Yaling

hanyl@medmail.com.cn+86 024 23051120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026